Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.96 USD | -0.50% | -5.77% | +26.33% |
05-24 | JPMorgan Adjusts Price Target on Cellebrite DI to $14 From $12, Maintains Overweight Rating | MT |
05-24 | Deutsche Bank Adjusts Price Target on Cellebrite to $15 From $13, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.33% | 2.26B | |
+14.48% | 3,198B | |
+12.56% | 90.08B | |
+6.60% | 80.61B | |
-14.00% | 54.83B | |
+21.67% | 46.88B | |
+32.37% | 46.51B | |
-31.29% | 42.9B | |
+67.09% | 39.99B | |
-1.54% | 26.87B |
- Stock Market
- Equities
- CLBT Stock
- News Cellebrite DI Ltd.
- Earnings Flash (CLBT) CELLEBRITE Reports Q3 Revenue $65.9M, vs. Street Est of $59.3M